U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07065500) titled 'Mechanism and Effect of Novel Metabolites on Valvular Heart Disease' on July 02.
Brief Summary: Valvular heart disease (VHD) is a leading cause of loss of physical function, reduced quality of life and increased longevity.The epidemiology of VHD varies widely across the globe, with functional and degenerative diseases occurring predominantly in high-income countries and rheumatic heart disease occurring predominantly in low- and middle-income countries. The prevalence of valvular heart disease (VHD) is increasing globally due to improved survival and aging populations, poorly controlled by medications, with the majority of patients ...